Neospora caninum: a new class of biopharmaceuticals in the therapeutic arsenal against cancer.
Louis LantierAgathe Poupée-BeaugéAnne di TommasoCéline DucournauMathieu EpardaudZineb LakhrifStéphanie GermonFrançoise Debierre-GrockiegoMarie-Noëlle MévélecArthur BattistoniLoïs CoënonNora Deluce-Kakwata-NkorFlorence Velge-RousselCéline BeauvillainThomas BaranekGordon Scott LeeThibault KervarrecAntoine TouzéNathalie MoiréIsabelle Dimier-PoissonPublished in: Journal for immunotherapy of cancer (2021)
These results highlight N. caninum as a potential, extremely effective and non-toxic anticancer agent, capable of being engineered to either express at its surface or to secrete biodrugs. Our work has identified the broad clinical possibilities of using N. caninum as an oncolytic protozoan in human medicine.